MEGESTROL ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1971)
Entry Type: Small molecule
Molecule Category: Parent
UNII: TJ2M0FR8ES
Parent Compound: MEGESTROL

Structure
InChI Key RQZAXGRLVPAYTJ-GQFGMJRRSA-N
Smile CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChI
InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H32O4
Molecular Weight 384.52
AlogP 4.58
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 2.0
Polar Surface Area 60.44
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Progesterone receptor agonist PubMed PubMed Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 51
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 17800 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Cachexia 4 D002100 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Endometrial Hyperplasia 3 D004714 ClinicalTrials
Hot Flashes 3 D019584 ClinicalTrials
Liver Neoplasms 3 D008113 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
HIV Wasting Syndrome 2 D019247 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Dementia 2 D003704 ClinicalTrials
Carcinoma in Situ 2 D002278 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 2 D029424 ClinicalTrials
Uterine Neoplasms 2 D014594 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.24
Metabolism and nutrition disorders
11.9
Endocrine disorders
8.93
Psychiatric disorders
8.78
Nervous system disorders
7.74
Gastrointestinal disorders
7.44
Investigations
7.14
Vascular disorders
6.7
Reproductive system and breast disorders
4.32
Respiratory, thoracic and mediastinal disorders
3.57
Injury, poisoning and procedural complications
3.27
Cardiac disorders
2.98

Cross References

Resources Reference
CAS NUMBER 595-33-5
ChEBI 6723
ChEMBL CHEMBL1201139
DrugBank DB00351
DrugCentral 1667
EPA CompTox DTXSID9040683
FDA SRS TJ2M0FR8ES
KEGG C08151
PubChem 11683
SureChEMBL SCHEMBL745
ZINC ZINC000004097467
CONTENTS